Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancer

pharmaceutical-business-reviewMarch 06, 2020

Tag: cancer , anti-CTLA-4 , Harbour BioMed , HBM4003

PharmaSources Customer Service